0 355

Cited 18 times in

Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents

Authors
 Yehyun Park  ;  Jae Hee Cheon 
Citation
 Current Gastroenterology Reports, Vol.22(5) : 24, 2020-03 
Journal Title
Current Gastroenterology Reports
ISSN
 1522-8037 
Issue Date
2020-03
Keywords
Behcet’s disease ; Gastrointestinal Behcet’s disease ; Small bowel
Abstract
Purpose of review: The treatment of intestinal Behcet's disease (BD) is challenging, and one-third of patients require surgery due to failure of conventional therapies. Anti-tumor necrosis factor-α (TNF-α) and other new biologics have been actively investigated for managing intestinal BD. In this article, we review the updated experiences and up-to-date clinical data on anti-TNF-α and other biologics for the management of intestinal BD.

Recent findings: Recent prospective studies have proved the efficacy and safety of infliximab and adalimumab for treating intestinal BD. Recent studies with other biologics such as anti-interleukin (IL)-1 (anakinra and canakinumab) and anti-IL-6 (tocilizumab) have shown promising results in patients with systemic, including intestinal, BD. Both infliximab and adalimumab can be useful in managing patients with intestinal BD, especially severe or refractory cases, with a similar efficacy and safety profile. More evidence for anakinra, canakinumab, tocilizumab, anti-IL-17 (secukinumab), and anti-IL-12/23 (ustekinumab) in intestinal BD is required.
Full Text
https://link.springer.com/article/10.1007%2Fs11894-020-00759-1
DOI
10.1007/s11894-020-00759-1
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Yehyun(박예현) ORCID logo https://orcid.org/0000-0001-8811-0631
Cheon, Jae Hee(천재희) ORCID logo https://orcid.org/0000-0002-2282-8904
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/179071
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links